Analysts expect a surge in US-China biotech deals as US restrictions appear less likely
- Nomura’s Jialin Zhang is identified as the head of China healthcare research.
- Out-licensing deals between China and the US are anticipated to increase.
- Beijing’s five-year plan for the biotech sector is referenced as context for optimism.
- The US Treasury Department was drafting investment measures.
